Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors

首页> 外文期刊>Prescrire international >Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors

【24h】

Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors

机译：法国的阿尔茨海默氏病：太多患者暴露于涉及胆碱酯酶抑制剂的药物相互作用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

A study based on data from the French national health insurance system, for the period 2003-2011, has shown that patients with Alzheimer's disease receiving a cholinesterase inhibitor were exposed to another drug that reduces the heart rate in about 44% of cases, a neuroleptic in 33% of cases, and an antimuscarinic for urinary problems in 8% of cases. Drugs for Alzheimer's disease expose patients to dangerous drug-drug interactions.

机译：根据法国国家健康保险系统（2003-2011年）的数据进行的一项研究表明，接受胆碱酯酶抑制剂的阿尔茨海默氏病患者暴露于另一种可降低心率的药物中，这是一种精神抑制药在33％的病例中使用抗毒蕈碱药，在8％的病例中使用抗毒蕈碱药。用于治疗阿尔茨海默氏病的药物会使患者面临危险的药物相互作用。

著录项

来源
《Prescrire international》 |2014年第150期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors [J] . Prescrire international . 2014,第150期

机译：法国的阿尔茨海默氏病：太多患者暴露于涉及胆碱酯酶抑制剂的药物相互作用
2. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). [J] . Tavassoli N, Sommet A, Lapeyre-Mestre M, Drug safety: An international journal of medical toxicology and drug experience . 2007,第11期

机译：药物与胆碱酯酶抑制剂的相互作用：对法国药物警戒数据库的分析，并比较了两种国家药物配方（维达尔，英国国家配方）。
3. Drug Persistency of Two Cholinesterase Inhibitors : Rivastigmine versus Donepezil in Elderly Patients with Alzheimer's Disease. [J] . Suh DC, Thomas SK, Valiyeva E, Drugs and aging . 2005,第8期

机译：阿尔茨海默氏病老年患者中两种胆碱酯酶抑制剂的药物持久性：利伐斯明与多奈哌齐。
4. Improving adherence and persistence to cholinesterase inhibitor therapy in Alzheimer's disease: development of the CaretoCare? caregiver support program [C] . Brady R., Walburn J., Weinman J., International Conference of Alzheimer's Disease International . 2012

机译：在阿尔茨海默病的胆碱酯酶抑制剂治疗中提高依从性和持续性：Caretocare的发展？护理人员支持计划
5. A Retrospective Study of Cholinesterase Inhibitors for Alzheimer's Disease: The Effect of Cerebrovascular Disease on Patient Outcomes and the Impact of Biases on the Results. [D] . Charbonneau, Claudie. 2011

机译：胆碱酯酶抑制剂对阿尔茨海默氏病的回顾性研究：脑血管疾病对患者结果的影响以及偏见对结果的影响。
6. The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial [O] . Christopher L.H. Chen, Purabi Reang Sharma, Boon Yeow Tan, 2015

机译：NEuroaid（ATHENE）研究阿尔茨海默氏病的研究方案：评估神经碱II（MLC901）在胆碱酯酶抑制剂或美金刚稳定的轻度至中度阿尔茨海默氏病患者中的安全性和有效性-随机，双盲，安慰剂对照试用
7. PNL5 DRUG PERSISTENCY OF TWO CHOLINESTERASE INHIBITORS—RIVASTIGMINE VERSUS DONEPEZIL AMONG ELDERLY PATIENTS WITH ALZHEIMER'S DISEASE [O] . Suh DC, Thomas SK, Valiyeva E, 2005

机译：老年性痴呆患者中两种胆碱酯酶抑制剂PNS5药物的持久性—利福斯丁定与多奈哌齐

Alzheimer's disease in France: too many patients exposed to drug interactions involving cholinesterase inhibitors

摘要

著录项

相似文献

相关主题

期刊订阅